Mainz Biomed has teamed up with Quest Diagnostics to advance the commercialization of its ColoAlert colorectal cancer screening test. Quest will provide lab services for Mainz’s 15,000-subject ReconAAsense study, aimed at securing FDA approval. If approved, Quest may secure semi-exclusive testing rights for 18 months. ColoAlert, a stool-based PCR test, shows promise in detecting colorectal cancer and advanced adenomas early.
Quest to provide services for Mainz Biomed CRC test clinical trials (Lab Pulse)
0